Zentralklinik Bad Berka

Zentralklinik Bad Berka is a modern, supra-regional hospital and academic teaching hospital in Germany, offering advanced diagnostics and therapies across 21 specialist clinics and centers. It provides a wide range of inpatient and outpatient treatments, including neurosurgery, nuclear medicine (PET/CT, radiosynoviorthesis, radionuclide therapy), oncology, and spine surgery. The hospital is known for its expertise in treating neuroendocrine tumors and offers innovative radiotherapies such as Xofigo (radium-223 dichloride) for prostate cancer with bone metastases and peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors. The hospital also develops radiopharmaceuticals in-house using a cyclotron facility.